Cohance Lifesciences Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
COHANCE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Cohance Lifesciences (formerly Suven Pharmaceuticals) reported its first full quarter as a merged entity, with consolidated revenue rising 13% year-on-year to ₹549.31 crore (standalone: ₹483.58 crore, marginally lower than restated ₹488.08 crore). Net profit attributable to shareholders fell to ₹48.88 crore on a consolidated basis (standalone: ₹52.57 crore) compared with ₹75.37-75.45 crore in Q1FY25, partly hit by an exceptional item of ₹8.10 crore for one-time merger restructuring expenses. Gross margins improved to 73.0% from 68.4% a year ago, while adjusted EBITDA stood at ₹1,314 million with a 23.9% margin. The company highlighted that excluding temporary pharma CDMO inventory destocking, underlying revenue growth exceeded 25%, with niche technology revenues now contributing over 20% of sales versus mid-teens in FY25.
Mixed quarter for shareholders — topline growth on a consolidated basis is healthy and margin trends are positive, but reported profits declined year-on-year because of merger-related exceptional costs and integration spend. Investors should note that prior-period figures have been restated following the amalgamation, so YoY comparisons need to be read carefully; the strategic direction (niche modalities like ADCs and oligonucleotides, new CEO appointment) is a positive long-term signal.